Setpoint Medical VNS for rheumatoid arthritis: pivotal randomized controlled trial in Nature 2025
Summary
The pivotal randomized controlled trial of Setpoint Medical's implantable vagus nerve stimulator for rheumatoid arthritis was published in Nature in 2025. The trial demonstrated significant reduction in disease activity scores in patients who had failed biologic therapies. The bioelectronic device stimulates the vagus nerve to activate the cholinergic anti-inflammatory pathway, suppressing TNF and IL-6 production systemically without immunosuppression. This is the first pivotal bioelectronic medicine trial published in Nature.
Why it matters
Nature publication of a pivotal bioelectronic medicine RCT is an extraordinary scientific milestone — Nature very rarely publishes clinical trials, reserving that space for paradigm-shifting results. Setpoint's trial data reaching Nature signals this is not a marginal treatment but a genuinely transformative approach to autoimmune disease management.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial